Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2022 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $90000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 89.77% year-over-year to $90000.0; the TTM value through Mar 2026 reached $90000.0, down 89.77%, while the annual FY2025 figure was $90000.0, 89.77% down from the prior year.
  • Other Non-Current Liabilities hit $90000.0 in Q1 2026 for Agios Pharmaceuticals, roughly flat from $90000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.3 million in Q4 2022 and bottomed at $90000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $985562.5, with a median of $1.1 million recorded in 2022.
  • Year-over-year, Other Non-Current Liabilities grew 9.57% in 2023 and then crashed 92.21% in 2025.
  • Agios Pharmaceuticals' Other Non-Current Liabilities stood at $3.3 million in 2022, then crashed by 64.75% to $1.2 million in 2023, then decreased by 23.88% to $880000.0 in 2024, then plummeted by 89.77% to $90000.0 in 2025, then changed by 0.0% to $90000.0 in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $90000.0, $90000.0, and $90000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.